NanoString Technologies Enters into Biomarker Companion Diagnostic Collaboration with Celgene Corporation to Support Development of REVLIMID as Treatm

04-06-2014 Business Wire HealthComments (0)


Celgene and NanoString Technologies are collaborating to develop a companion diagnostic assay to support the clinical validation of REVLIMID for treatment of Diffuse Large B-Cell Lymphoma (DLBCL).

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top